(Total Views: 730)
Posted On: 12/11/2020 4:19:38 PM
Post# of 148902
PARTNERSHIPS ARE FOR SUCKERS. MILD TO MODERATE IS USELESS.
Oh wait...maybe they're not. But don't question NP...nope, not at all. EVER.
Link to full article:
https://finance.yahoo.com/news/thiel-backed-d...04431.html
(Bloomberg) -- AbCellera Biologics Inc., which is developing an antibody treatment for Covid-19 with Eli Lilly & Co., tripled at the opening of trading after its initial public offering.
Shares of the Vancouver-based company opened at $61 after being priced at $20 in the offering. The offering raised $483 million before commissions and expenses, making it the biggest Canadian pharmaceuticals IPO on record and the second-largest Canadian initial offering announced this year, according to data compiled by Bloomberg.
AbCellera is riding a wave of interest in companies whose products may be used to combat the pandemic. The firm is co-developing a monoclonal antibody treatment that U.S. regulators authorized last month as a therapy for people with mild-to-moderate Covid-19 symptoms.
Oh wait...maybe they're not. But don't question NP...nope, not at all. EVER.
Link to full article:
https://finance.yahoo.com/news/thiel-backed-d...04431.html
(Bloomberg) -- AbCellera Biologics Inc., which is developing an antibody treatment for Covid-19 with Eli Lilly & Co., tripled at the opening of trading after its initial public offering.
Shares of the Vancouver-based company opened at $61 after being priced at $20 in the offering. The offering raised $483 million before commissions and expenses, making it the biggest Canadian pharmaceuticals IPO on record and the second-largest Canadian initial offering announced this year, according to data compiled by Bloomberg.
AbCellera is riding a wave of interest in companies whose products may be used to combat the pandemic. The firm is co-developing a monoclonal antibody treatment that U.S. regulators authorized last month as a therapy for people with mild-to-moderate Covid-19 symptoms.
(4)
(0)Scroll down for more posts ▼
